New collaboration for affordable COVID-19 drug 2-DGJuly 1, 2021
New Delhi: Indian Institute of Chemical Technology (IICT), Hyderabad, a constituent laboratory of Council of Scientific and Industrial Research (CSIR), New Delhi, and Nosch Labs entered into a non-exclusive agreement for the transfer of the process knowhow for the synthesis of anti-Covid-19 drug 2-DG (2-Deoxy -D -Glucose).
2-DG has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), New Delhi, a lab of the Defence Research and Development Organisation (DRDO), in collaboration with Hyderabad-based pharma company Dr Reddy’s Laboratories (DRL).
Nosch Labs will commence manufacturing 2-DG drug after obtaining regulatory clearances from the Drugs Controller General of India (DCGI). The company intends to make the drug available at an affordable price.
“The institute has been instrumental in addressing numerous societal challenges and providing innovative solutions to Indian industries in the area of drugs & pharmaceuticals, agrochemicals, lipids, catalysis, functional materials, environmental, analytical, biological and engineering sciences. The institute has also undertaken clinical trials of various drugs repurposed to treat people infected with COVID-19”, said Dr. Srivari Chandrasekhar, Director CSIR-IICT.
CSIR-IICTwith its expertise in chemistry and chemical technology provides solutions to challenges faced by the industry, government departments, and entrepreneurs through basic and applied research, and process development. It is internationally recognized for its contributions to chemistry research and is considered an ideal place for taking ideas to commercialization through state-of-the-art research and development.
Nosch Labs Pvt. Ltd, with headquarters in Hyderabad, has four manufacturing facilities in Telangana. The company with an annual turnover of Rs 500 crores, has international regulatory accreditation such as EU GMP, Korea GMP and Russian GMP certifications. The company manufactures anti-ulcer, anti-fungal, anti-depressant, APIs, semi-finished and finished formulations. It exports to more than 40 countries including Europe, South America, Russia, China and Korea, CSIR-IICT statement said. (India Science Wire)